Androgen deprivation treatment is the main treatment for metastatic prostate cancer, while combined androgen blockade therapy can prolong the overall survival and progression-free survival of prostate cancer patients.[3] However, after 18 to 24 months of androgen deprivation treatment, prostate cancer cells can adapt to the low testosterone status by increasing the expression of their androgen receptor, can also generate testosterone in the tumor microenvironment by autocrine and paracrine, and activation of other signal pathways, which can remove the maximum inhibition of AR. The gene discussed is AR; the disease is metastatic prostate carcinoma.